Lifecore Biomedical's (LFCR) Sell (D) Rating Reaffirmed at Weiss Ratings

Key Points

• Lifecore Biomedical's stock is reaffirmed with a "sell (d)" rating by Weiss Ratings, while other analysts have mixed ratings with two Buy, two Hold, and one Sell.
• The company's recent earnings report showed a loss of ($0.10) EPS, missing expectations, despite revenue surpassing estimates.
• Lifecore has a market cap of $257.39 million and a current stock price around $6.87, with a one-year price range of $4.33 to $8.85.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report)'s stock had its "sell (d)" rating reissued by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Other equities analysts also recently issued research reports about the company. Wall Street Zen upgraded Lifecore Biomedical from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. KeyCorp initiated coverage on Lifecore Biomedical in a research report on Wednesday, September 3rd. They set a "sector weight" rating on the stock. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $8.00.

Lifecore Biomedical Stock Performance

Shares of Lifecore Biomedical stock opened at $6.87 on Wednesday. Lifecore Biomedical has a one year low of $4.33 and a one year high of $8.85. The company has a market cap of $257.39 million, a price-to-earnings ratio of -5.24 and a beta of 0.62. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.77 and a current ratio of 2.84. The business's 50 day moving average price is $7.41 and its 200 day moving average price is $7.11.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%.The company had revenue of $36.44 million for the quarter, compared to analysts' expectations of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS. On average, research analysts predict that Lifecore Biomedical will post -0.91 EPS for the current year.

Institutional Investors Weigh In On Lifecore Biomedical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LFCR. GAMMA Investing LLC raised its position in Lifecore Biomedical by 1,839.7% in the first quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock valued at $25,000 after purchasing an additional 3,385 shares during the period. Summit Securities Group LLC purchased a new stake in Lifecore Biomedical in the first quarter valued at $26,000. Hurley Capital LLC acquired a new stake in shares of Lifecore Biomedical in the first quarter valued at $35,000. State of Wyoming acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at $69,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at $88,000. Hedge funds and other institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.